Neuroblastoma in Children: Symptoms, Diagnosis, and Breakthrough Treatments

Neuroblastoma is a cancer that develops from immature nerve cells, known as neuroblasts, and most often begins in the adrenal glands. It can arise anywhere along the sympathetic nervous system. In children, the disease can behave very differentlyfrom tumors that respond quickly to therapy to forms that require intensive, multimodality treatment. This article outlines the common signs to watch for, how doctors diagnose neuroblastoma, and the latest breakthroughs shaping care for affected children.

Symptoms and Early Clues

• Abdominal or chest mass that can be felt by a parent or clinician.
• Persistent pain, swelling, or fullness in the abdomen; occasional constipation or urinary symptoms from tumor pressure.
• Unexplained fever, weight loss, or fatigue.
• Bone pain or limp if the cancer has spread to bones or joints.
• Rare neurological signs such as opsoclonusmyoclonus syndrome or other paraneoplastic symptoms.

Because symptoms can resemble common childhood illnesses, a careful evaluation by a pediatric oncologist is recommended when signs persist or recur.

Diagnosis: How Doctors Confirm Neuroblastoma

1. Biochemical testing: Urine or blood tests look for elevated catecholamine metabolites, especially vanillylmandelic acid (VMA) and homovanillic acid (HVA).
2. Imaging: Ultrasound, CT, or MRI identify the tumor’s size, location, and involvement of nearby structures.
3. Functional imaging: An MIBG scan helps map disease throughout the body by targeting neuroblastoma cells.
4. Biopsy and pathology: A tissue sample confirms the diagnosis and reveals tumor characteristics, including genetic features such as MYCN amplification.
5. Risk stratification: Age at diagnosis, stage, and tumor biology guide the risk category and treatment plan.

Breakthrough Treatments and Multimodal Care

Treatment is tailored to risk level and tumor biology. For many children with localized disease, surgery to remove the tumor is followed by chemotherapy and, in some cases, radiation therapy. High‐risk neuroblastoma, meanwhile, uses a combination of modalities to maximize cure chances while attempting to limit late effects.

• Surgery: Removing as much tumor as safely possible upfront is a key step when feasible.
• Chemotherapy: Pre and postsurgical chemotherapy reduces tumor burden and helps control disease spread.
• Radiation therapy: Used selectively to target residual disease or metastatic sites.
• Highdose chemotherapy with autologous stem cell rescue (ASCT): Enables intensified chemotherapy in highrisk patients while restoring the blood system.
• Immunotherapy and biologic agents: AntiGD2 antibodies (such as dinutuximab) with supportive cytokines form a central part of modern highrisk regimens, improving longterm outcomes.
• Targeted therapies and trials: Treatments aimed at specific genetic changes (like ALK mutations) are used when present, and ongoing clinical trials explore new combinations and modalities.
• MIBG radiopharmaceutical therapy: 131IMIBG delivers targeted radiation to neuroblastoma cells in the body and is used in certain relapsed or refractory cases or within trial protocols.
• Maintenance and differentiation therapy: Retinoids (e.g., 13cisretinoic acid) can help sustain remission after successful initial therapy.

Prognosis and Survivorship

Outcomes vary widely based on age at diagnosis, stage, and tumor biology. Young children with biologically favorable tumors often have better results, while metastasis, MYCN amplification, or certain tumor locations can indicate higher risk. Advances in therapy have improved survival for many, but late effectssuch as hearing loss, growth disturbances, or secondary cancerscan occur, underscoring the need for longterm followup with a multidisciplinary team.

Questions to Discuss with Your Care Team

• What is the tumor’s risk category and what biology factors are known (MYCN, ALK, etc.)?
• What are the proposed treatment steps, and why are they chosen for this case?
• What are potential short and longterm side effects, and how will they be managed?
• Are there relevant clinical trials available, and how might participation help?
• What does followup look like after therapy ends?

Staying informed and connected with a pediatric oncology team helps families navigate treatment decisions and plan for the next steps. Ongoing research continues to bring new therapies and combinations that improve outcomes and quality of life for children facing this disease.